Sign inJoin waitlistJoin the waitlist

Anastasios Manessis

Clinical Instructor · NYU Grossman School of Medicine

Credentials: · ·

History

NYU Grossman School of Medicine
Present
Cornell Univ Joan and Sanford I Weill Med Coll · New York Presbyterian Hospital
Present

Endocrinology, Diabetes, and Metabolism
2008–2010
St. Vincent's Hospital
2007–2008
St. Vincent's Hospital
2002–2005
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
1997–2001

Research

Disruption of IcsP, the major Shigella protease that cleaves IcsA, accelerates actin-based motility
Molecular Microbiology · 1997 · 103 citations
A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of…
Diabetes Care · 2024 · 26 citations
Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active…
Case report · Endocrine Practice · 2011 · 22 citations

Halis Akturk
3 papers
Irl Hirsch
3 papers
TB
Thomas Blevins
3 papers
Yogish Kudva
3 papers
AB
Anju Bhargava
2 papers
Bruce Bode
2 papers
Carol Levy
2 papers
CJ
Christopher Jacobson
2 papers
DP
David Pickering
2 papers
Devin Steenkamp
2 papers
Donna Desjardins
2 papers
Grazia Aleppo
2 papers

Clinical trials

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2026–2030
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2026–2028
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2028
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031